Adjuvant Ipilimumab in Melanoma: Future in Doubt Adjuvant Ipilimumab in Melanoma: Future in Doubt
This hugely expensive regimen has now been eclipsed by the checkpoint inhibitor nivolumab, placing the future of adjuvant ipilimumab under question, argues one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Merck Hedges Bets With Keytruda Lung Study
Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with Yervoy, a drug made by rival Bristol-Myers Squibb. But don ' t interpret the study as a bet the combination will prove effective. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 6, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news
First Randomized Study To Evaluate IMLYGIC ® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
Results Demonstrated a Doubling of Objective Response Rate Compared to Ipilimumab Alone in Unresectable Advanced Melanoma
Responses Were Not Limited to Injected Lesions and Favored the Combination Arm Across Subsets of Disease
THOUSAND OAKS, Calif., Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary endpoint of objective response rate (ORR), demonstrating that IMLYGIC in combination with YERVOY® (ipilimumab) more than doubled ORR, defined as t...
Source: Amgen News Release - October 5, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Three-year survival rates with advanced melanoma are 52% with nivolumab and 34% with ipilimumab, but 58% with a sequential combination of the two, according to the latest results comparing the two anticancer biologics separately and together.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adjuvant Nivolumab Tops Ipilimumab in Melanoma
Longer recurrence - free survival for stage IIIB, IIIC, IV melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 12, 2017 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news
Clear Benefit With Adjuvant Nivolumab in Resected Melanoma Clear Benefit With Adjuvant Nivolumab in Resected Melanoma
Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit
The median PFS for the combination group was 11.6 months (95% CI: 8.71 to 15.51) versus 8.4 months (95% CI: 7.0 to 10.8) for the sunitinib group.09/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2017 Category: Urology & Nephrology Source Type: news
Immunotherapy Changes First-Line Paradigm in Advanced RCC Immunotherapy Changes First-Line Paradigm in Advanced RCC
For the first time, sunitinib has been beaten in a phase 3 trial; the combination of nivolumab and ipilimumab showed a significant improvement in overall survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
(European Society for Medical Oncology) Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. The anti-programmed death-1 (PD-1) antibody nivolumab led to better relapse-free survival, with fewer side effects than ipilimumab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news
After melanoma surgery, Bristol's Opdivo offers new care standard
MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 16, 2017 Category: Urology & Nephrology Source Type: news
BMS Phase III ’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb announces topline results from CheckMate -214
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma. (Source: World Pharma News)
Source: World Pharma News - August 15, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Pembrolizumab Plus Reduced Ipilimumab Dose Active in Advanced Melanoma
Standard-dose pembrolizumab with four reduced doses of ipilimumab followed by standard-dose pembrolizumab had a manageable safety profile and antitumor activity in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news
